Hikma Pharmaceuticals/£HIK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC, operating under the ticker HIK, is a multinational pharmaceutical company. Founded in 1978 and headquartered in London, UK, it specializes in developing, manufacturing, and marketing both branded and non-branded generic and in-licensed pharmaceutical products. The company operates within the healthcare sector, focusing on a broad range of therapeutic areas.
Ticker
£HIK
Sector
Primary listing
LSE
Industry
Pharmaceuticals
Headquarters
Employees
9,500
ISIN
GB00B0LCW083
Website
HIK Metrics
BasicAdvanced
£4.4B
17.02
£1.17
0.45
£0.80
4.01%
Price and volume
Market cap
£4.4B
Beta
0.45
52-week high
£23.60
52-week low
£17.51
Average daily volume
520K
Dividend rate
£0.80
Financial strength
Current ratio
1.144
Quick ratio
0.6
Long term debt to equity
28.134
Total debt to equity
56.269
Dividend payout ratio (TTM)
48.75%
Interest coverage (TTM)
6.39%
Profitability
EBITDA (TTM)
557.472
Gross margin (TTM)
45.25%
Net profit margin (TTM)
11.48%
Operating margin (TTM)
19.44%
Effective tax rate (TTM)
20.44%
Revenue per employee (TTM)
£240,160
Management effectiveness
Return on assets (TTM)
7.57%
Return on equity (TTM)
15.98%
Valuation
Price to earnings (TTM)
17.018
Price to revenue (TTM)
1.939
Price to book
1.9
Price to tangible book (TTM)
3.81
Price to free cash flow (TTM)
18.432
Free cash flow yield (TTM)
5.43%
Free cash flow per share (TTM)
108.18%
Dividend yield (TTM)
4.01%
Growth
Revenue change (TTM)
8.77%
Earnings per share change (TTM)
89.41%
3-year revenue growth (CAGR)
6.99%
10-year revenue growth (CAGR)
7.70%
3-year earnings per share growth (CAGR)
-3.77%
10-year earnings per share growth (CAGR)
1.48%
3-year dividend per share growth (CAGR)
14.00%
10-year dividend per share growth (CAGR)
13.78%
What the Analysts think about HIK
Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.
Bulls say / Bears say
Hikma Pharmaceuticals is preparing to launch generic versions of Novo Nordisk's blockbuster obesity drugs, Ozempic and Wegovy, as their patents begin to expire, potentially capturing a significant share of the $80bn to $140bn global weight loss drug market. (ft.com)
The company reported a 19% increase in core operating profit to $707 million in 2023, surpassing analyst expectations and demonstrating strong performance in its generics business. (reuters.com)
Hikma has raised its full-year guidance, now forecasting revenue growth of 6-8% and core operating profit between $700 million and $730 million, reflecting confidence in sustained growth across its divisions. (investing.com)
Hikma Pharmaceuticals agreed to pay $50 million to settle a class action lawsuit alleging collusion with Jazz Pharmaceuticals to delay the release of a generic version of the narcolepsy drug Xyrem, which could impact its financial position and reputation. (reuters.com)
The company anticipates a slight decline in profit for 2024, projecting a core operating profit range of $660 million to $700 million, compared to $707 million in 2023, indicating potential challenges in maintaining profit growth. (reuters.com)
Hikma has reached an agreement in principle to pay up to $115 million in cash and $35 million in naloxone donations to resolve opioid-related claims in the U.S., which may affect its financial resources and public perception. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
HIK Financial Performance
Revenues and expenses
HIK Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hikma Pharmaceuticals stock?
Hikma Pharmaceuticals (HIK) has a market cap of £4.4B as of July 01, 2025.
What is the P/E ratio for Hikma Pharmaceuticals stock?
The price to earnings (P/E) ratio for Hikma Pharmaceuticals (HIK) stock is 17.02 as of July 01, 2025.
Does Hikma Pharmaceuticals stock pay dividends?
Yes, the Hikma Pharmaceuticals (HIK) stock pays dividends to shareholders. As of July 01, 2025, the dividend rate is £0.8 and the yield is 4.01%. Hikma Pharmaceuticals has a payout ratio of 48.75% on a trailing twelve-month basis.
When is the next Hikma Pharmaceuticals dividend payment date?
The next Hikma Pharmaceuticals (HIK) dividend payment date is unconfirmed.
What is the beta indicator for Hikma Pharmaceuticals?
Hikma Pharmaceuticals (HIK) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.